HLS Therapeutics Inc
TSX:HLS
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
CA |
HLS Therapeutics Inc
TSX:HLS
|
125.6m CAD | 13.6 | ||
US |
Mckesson Corp
NYSE:MCK
|
73.3B USD | 16.3 | ||
US |
Cencora Inc
NYSE:COR
|
44.1B USD | 11.7 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 11.3 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
24B USD | 8.9 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 12.4 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 1.7 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.6B EUR | 15.3 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 14.8 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | 8.5 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.